[go: up one dir, main page]

WO2002032375A8 - Uses of monoclonal antibody 8h9 - Google Patents

Uses of monoclonal antibody 8h9

Info

Publication number
WO2002032375A8
WO2002032375A8 PCT/US2001/032565 US0132565W WO0232375A8 WO 2002032375 A8 WO2002032375 A8 WO 2002032375A8 US 0132565 W US0132565 W US 0132565W WO 0232375 A8 WO0232375 A8 WO 0232375A8
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
provides
derivative
binding
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/032565
Other languages
French (fr)
Other versions
WO2002032375A2 (en
WO2002032375A9 (en
WO2002032375A3 (en
Inventor
Nai-Kong V Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002423843A priority Critical patent/CA2423843A1/en
Priority to AU2002215383A priority patent/AU2002215383A1/en
Priority to EP01983999A priority patent/EP1399187A4/en
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to US10/097,558 priority patent/US7737258B2/en
Publication of WO2002032375A2 publication Critical patent/WO2002032375A2/en
Publication of WO2002032375A3 publication Critical patent/WO2002032375A3/en
Publication of WO2002032375A8 publication Critical patent/WO2002032375A8/en
Priority to US10/273,762 priority patent/US7666424B2/en
Priority to EP02801782A priority patent/EP1441765A4/en
Priority to CA2463017A priority patent/CA2463017C/en
Priority to AU2002362846A priority patent/AU2002362846A1/en
Priority to PCT/US2002/033331 priority patent/WO2003033670A2/en
Publication of WO2002032375A9 publication Critical patent/WO2002032375A9/en
Priority to US10/505,658 priority patent/US7740845B2/en
Anticipated expiration legal-status Critical
Priority to US12/709,848 priority patent/US8148154B2/en
Priority to US12/721,798 priority patent/US8414892B2/en
Priority to US12/797,081 priority patent/US8501471B2/en
Priority to US13/858,234 priority patent/US9062110B2/en
Priority to US13/958,902 priority patent/US20140161814A1/en
Priority to US15/365,803 priority patent/US9938351B2/en
Priority to US15/899,801 priority patent/US20180208673A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.
PCT/US2001/032565 2000-10-18 2001-10-18 Uses of monoclonal antibody 8h9 Ceased WO2002032375A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CA002423843A CA2423843A1 (en) 2000-10-18 2001-10-18 Uses of monoclonal antibody 8h9
AU2002215383A AU2002215383A1 (en) 2000-10-18 2001-10-18 Uses of monoclonal antibody 8h9
EP01983999A EP1399187A4 (en) 2000-10-18 2001-10-18 USES OF MONOCLONAL ANTIBODY 8H9
US10/097,558 US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
AU2002362846A AU2002362846A1 (en) 2001-10-17 2002-10-17 Method for preparation of single chain antibodies
US10/273,762 US7666424B2 (en) 2001-10-17 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
PCT/US2002/033331 WO2003033670A2 (en) 2001-10-17 2002-10-17 Method for preparation of single chain antibodies
EP02801782A EP1441765A4 (en) 2001-10-17 2002-10-17 Method for preparation of single chain antibodies
CA2463017A CA2463017C (en) 2001-10-17 2002-10-17 Method for preparation of single chain antibodies
US10/505,658 US7740845B2 (en) 2000-10-18 2003-03-06 Uses of monoclonal antibody 8H9
US12/709,848 US8148154B2 (en) 2001-10-17 2010-02-22 Method for preparation of single chain antibodies
US12/721,798 US8414892B2 (en) 2000-10-18 2010-03-11 Uses of monoclonal antibody 8H9
US12/797,081 US8501471B2 (en) 2000-10-18 2010-06-09 Uses of monoclonal antibody 8H9
US13/858,234 US9062110B2 (en) 2000-10-18 2013-04-08 Uses of monoclonial antibody 8H9
US13/958,902 US20140161814A1 (en) 2000-10-18 2013-08-05 Uses of monoclonal antibody 8h9
US15/365,803 US9938351B2 (en) 2000-10-18 2016-11-30 Uses of monoclonal antibody 8H9
US15/899,801 US20180208673A1 (en) 2000-10-18 2018-02-20 Uses of monoclonal antibody 8h9

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24134400P 2000-10-18 2000-10-18
US60/241,344 2000-10-18
US33039601P 2001-10-17 2001-10-17
US60/330,396 2001-10-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/982,645 Continuation-In-Part US20020102264A1 (en) 2000-10-18 2001-10-18 Uses of monoclonal antibody 8H9

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/097,558 Continuation-In-Part US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
US10/273,762 Continuation-In-Part US7666424B2 (en) 2000-10-18 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies

Publications (4)

Publication Number Publication Date
WO2002032375A2 WO2002032375A2 (en) 2002-04-25
WO2002032375A3 WO2002032375A3 (en) 2002-06-20
WO2002032375A8 true WO2002032375A8 (en) 2002-09-12
WO2002032375A9 WO2002032375A9 (en) 2003-01-03

Family

ID=26934217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032565 Ceased WO2002032375A2 (en) 2000-10-18 2001-10-18 Uses of monoclonal antibody 8h9

Country Status (3)

Country Link
EP (1) EP1399187A4 (en)
CA (1) CA2423843A1 (en)
WO (1) WO2002032375A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737258B2 (en) * 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
EP1511772B1 (en) 2002-05-28 2011-11-23 Omrix Biopharmaceuticals Inc. Method for obtaining anti-idiotype antibodies
DE60335022D1 (en) 2002-06-19 2010-12-30 Raven Biotechnologies Inc Internalizing antibodies specific for the RAAG10 cell surface target
AU2003298794A1 (en) * 2002-12-02 2004-06-23 Us Gov Health & Human Serv Recombinant immunotoxin and use in treating tumors
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
WO2006016276A2 (en) 2004-08-03 2006-02-16 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
EP3381937A3 (en) 2009-08-13 2018-10-31 The Johns Hopkins University Methods of modulating immune function
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
RU2692248C2 (en) 2014-02-14 2019-06-24 Макродженикс, Инк. Improved methods of treating vascularised malignant tumors
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
WO2016106004A1 (en) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof
KR20250079249A (en) 2015-10-08 2025-06-04 마크로제닉스, 인크. Combination therapy for the treatment of cancer
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021037319A1 (en) 2019-08-30 2021-03-04 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022167052A1 (en) 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212344A4 (en) * 1999-09-03 2004-08-04 Human Genome Sciences Inc POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES TYPE B7
AU2001283507A1 (en) * 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules

Also Published As

Publication number Publication date
EP1399187A2 (en) 2004-03-24
WO2002032375A2 (en) 2002-04-25
CA2423843A1 (en) 2002-04-25
WO2002032375A9 (en) 2003-01-03
WO2002032375A3 (en) 2002-06-20
EP1399187A4 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
WO2002032375A8 (en) Uses of monoclonal antibody 8h9
WO2003075846A3 (en) Uses of monoclonal antibody 8h9
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002022851A3 (en) Novel tumor-associated marker
WO2002030985A3 (en) Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
EP2336187B8 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
DE69939820D1 (en) INTERNALIZING ERBB2 ANTIBODIES
EP1308455A3 (en) A composition comprising anti-HER2 antibodies
AU4314900A (en) Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
EE05309B1 (en) β-Am Looid Peptide "Humanized Antibodies, Method for Their Preparation, Their Use, and Pharmaceutical Composition
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
AU6618100A (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
AU2002220843A1 (en) Humanised antibodies and uses thereof
EP2186884A3 (en) HCV-anti-core monoclonal antibody
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
AU7960600A (en) Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2002034290A3 (en) Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 6-11, DESCRIPTION, REPLACED BY NEW PAGES 6-11; PAGES 1/32-32/32, DRAWINGS, REPLACED BY NEW PAGES 1/32-32/32; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2423843

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2001983999

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001983999

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001983999

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP